(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...

Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...

In a positive move, last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Eisai Co., Ltd (OTC: ESALY) and Biogen’s ...

Oct 30 (Reuters) - Biogen (BIIB.O), opens new tab raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 29.8 ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis ...

(Reuters) - Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs. However, the drugmaker's ...

Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook ...

What do Amgen, Biogen, and Takeda have in common? Leaders of research and development at the three biopharma companies shared a stage Thursday at the STAT 2024 Summit in Boston and offered their ...

(RTTNews) - Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.

Recent rumours that Biogen was about to acquired by Samsung proved unfounded, but it turns out a deal has been in preparation. The South Korean firm just agreed to buy Biogen out of their ...